Trial of Direct Home Delivery of Colorectal Cancer Screening Kit Without Pre-ordering

NCT ID: NCT06032338

Last Updated: 2023-12-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

64000 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-09-14

Study Completion Date

2026-11-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The effect of mailing FIT with the invitation on participation and colonoscopy rates will be evaluated in a randomized controlled trial conducted in the Centre-Val de Loire (CVL) region, involving 64,000 people from the population eligible for colorectal cancer population-based organised screening program (CRC-PBOSP).

In the "C" control group, invitations, test delivery and reminders will be carried out in accordance with the CRC-PBOSP rules at the time of the study.

Intervention group "B" will evaluate two experimental modes of invitation with direct home mailing of the test:

* Method "B1": invitation with test sent to home without prior information letter
* Method "B2": information letter followed by invitation with test sent home, designed to optimize participation by first-time subjects (aged 50-51) invited to the CRC-PBOSP for the first time.

Ancillary studies will focus 1/ on acceptability of this intervention (qualitative study on a few general practitioners, gastroenterologists and invitees), 2/ on social and geographical inequalities of participation on a subsample of individuals included in EXPEDIT study using ecological indices (EDI, SCALE).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Screening Participation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The number of study arms will differ according to age-group:

* In 50 or 51 yrs age-group, individuals (n=5760 ) will be randomised in 3 groups: C, B1 and B2 (allocation ratio 2:1:1)
* In the age-group older than 51 yrs, individuals (n=58240) will be randomised in 2 groups: C, and B1 (allocation 1:1) In the main analysis including both age-groups, B1 and B2 arms would be pooled.
Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control "C"

Usual care : Screening test (Fecal immunochemical test - FIT) delivery and reminders will be carried out in accordance with the Colorectal cancer population-based organised screening program (CRC-PBOSP) specifications at the time of the study.

This arm is suitable for both the first screening round in 50-51 years old population, and for the subsequent screening rounds.

Group Type OTHER

CRC screening invitation not including the screening test.

Intervention Type OTHER

The invitation to CRC-PBOSP will only contain informations on how to get the screening test.

Intervention "B1"

FIT mailed at home within the CRC screening invitation without prior information letter.

This arm is suitable for both the first screening round in 50-51 years old population, and for the subsequent screening rounds.

Group Type EXPERIMENTAL

Mailing of FIT with invitation

Intervention Type OTHER

The invitation to CRC-PBOSP will contain the CRC screening test.

Intervention "B2"

FIT mailed at home within the CRC screening invitation with prior information letter.

This arm is suitable for the first screening round in 50-51 years old population only.

Group Type EXPERIMENTAL

Mailing of FIT with invitation

Intervention Type OTHER

The invitation to CRC-PBOSP will contain the CRC screening test.

Information letter before invitation

Intervention Type OTHER

An information letter will be sent to future invitees a few weeks before the invitation, to announce the mailing of the CRC screening kit.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CRC screening invitation not including the screening test.

The invitation to CRC-PBOSP will only contain informations on how to get the screening test.

Intervention Type OTHER

Mailing of FIT with invitation

The invitation to CRC-PBOSP will contain the CRC screening test.

Intervention Type OTHER

Information letter before invitation

An information letter will be sent to future invitees a few weeks before the invitation, to announce the mailing of the CRC screening kit.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 50 to 74 years old
* Resident of Centre Val de Loire French area
* Eligible for CRC screening invitation within the biennal CRC-PBOSP during the inclusion period
* Affiliated to the health insurance scheme

Exclusion Criteria

* Colonoscopy in the previous 5 years)

Subjects refusing data transmission to research team will be excluded from statistical analyses.
Minimum Eligible Age

50 Years

Maximum Eligible Age

74 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

Sponsor Role collaborator

Centre Régional de Coordination des Dépistages des Cancers (CRCDC) Centre Val de Loire

UNKNOWN

Sponsor Role collaborator

University Hospital, Caen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Crcdc-Cvl

Tours, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Lydia GUITTET, MD,PhD

Role: CONTACT

Phone: +33(0)231065781

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Julie BOYARD, ScD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022-A01914-39

Identifier Type: -

Identifier Source: org_study_id